LOTTE BIOLOGICS Forms New Manufacturing Partnership with Ottimo Pharma
LOTTE BIOLOGICS is excited to share recent developments in its global collaboration efforts. By signing a key contract with Ottimo Pharma, a leader in biopharmaceutical innovation, LOTTE BIOLOGICS continues to build its reputation in the competitive antibody therapeutics sector.
Strategic Collaboration for Antibody Therapeutics
The contract manufacturing agreement demonstrates LOTTE BIOLOGICS's strong commitment to supporting innovative healthcare solutions. Ottimo Pharma is known for developing unique PD1/VEGFR2 dual pathway antibodies designed to improve outcomes for patients battling cancer. This partnership allows LOTTE BIOLOGICS to produce essential antibody therapeutic substances at its cutting-edge Syracuse Bio Campus.
Insights from Leadership
James Park, CEO of LOTTE BIOLOGICS, expressed enthusiasm about the partnership, saying, "This agreement is yet another testament to our capability as a contract development and manufacturing organization (CDMO) within the global antibody landscape. We are dedicated to delivering high-quality pharmaceuticals that align with global standards, enhancing value for our partners and patients alike."
Joseph Shultz, Vice President of Technical Development & Manufacturing at Ottimo Pharma, also highlighted the significance of this collaboration. He stated, "Joining forces with LOTTE BIOLOGICS enhances our efficiency and operational readiness, driving us closer to our clinical trial aspirations with greater speed and precision. This collaboration is a major milestone in advancing our product, Jankistomig."
LOTTE BIOLOGICS's Global Operations
LOTTE BIOLOGICS has established a comprehensive portfolio of services at its Syracuse Bio Campus, ranging from cell line development to large-scale biopharmaceutical manufacturing. Moreover, the company is preparing to implement Plant 1 at its Songdo Bio Campus, aimed to be operational by 2027. This facility is expected to significantly enhance production capacity up to 120,000 liters, facilitating major contracts globally.
In recent months, LOTTE BIOLOGICS has actively expanded its collaborations with biopharmaceutical companies across different regions. By focusing on optimizing its two production sites, the company strengthens its presence in the CDMO market for both antibody therapeutics and antibody-drug conjugate (ADC) modalities, promising to deliver trustworthy and capable solutions.
Strategic Collaborations for Comprehensive Solutions
LOTTE BIOLOGICS is not just stopping at manufacturing; it is also working with global contract development organizations (CDOs) and drug product companies to craft personalized CDMO solutions. These partnerships guarantee a complete service range, from early development stages to commercial launch, tailored specifically for each client's needs.
About LOTTE BIOLOGICS
Headquartered in Seoul, LOTTE BIOLOGICS was launched with a clear mission: to create therapies that promote better health globally. At the Syracuse Bio Campus, the company provides high-quality Good Manufacturing Practice (GMP) services, demonstrating a broad production capacity of 40,000 liters, supported by advanced technology including eight stainless steel bioreactors of 5,000 liters capacity. This facility is complemented by robust analytical quality control testing labs and warehouse capabilities compliant with over 62 global regulatory bodies.
LOTTE BIOLOGICS continues to invest in new technologies; with over $100 million funneled into ADC modalities, they are expanding their services to offer comprehensive solutions all under one roof, encompassing both drug manufacturing and conjugation processes.
Future of LOTTE BIOLOGICS
Looking forward, LOTTE BIOLOGICS is embarking on the construction of three advanced biomanufacturing plants in Songdo, with plans for the first to begin operations by 2027. Each new facility will feature an impressive capacity, surpassing 360,000 liters when combined, ensuring that LOTTE BIOLOGICS can meet increasing global production demands.
Frequently Asked Questions
What is the main focus of the agreement between LOTTE BIOLOGICS and Ottimo Pharma?
The agreement centers on contract manufacturing for antibody therapeutics, which will aid Ottimo Pharma's product development.
Where will the manufacturing take place?
Manufacturing will occur at the Syracuse Bio Campus operated by LOTTE BIOLOGICS.
What are the future plans for LOTTE BIOLOGICS?
LOTTE BIOLOGICS plans to launch a new Plant 1 in Songdo by 2027, significantly increasing its production capacity.
How does LOTTE BIOLOGICS ensure quality in its manufacturing processes?
LOTTE BIOLOGICS adheres to Good Manufacturing Practice (GMP) standards and is certified by over 62 regulatory agencies worldwide.
What strategic collaborations is LOTTE BIOLOGICS pursuing?
LOTTE BIOLOGICS is collaborating with global CDOs and drug product companies to offer tailored, end-to-end services in drug development.
